

Acute renal failure

5% hospitalised patients

20% ITU patients

Defined as a rapid reduction on renal function over hours to days, with resultant impaired excretion of nitrogenous waste products. May be associated with oliguria

Classified as pre-renal, renal (intrinsic) or post-renal:

Pre-renal (50-70%)

Pump failure

MI

Arrhythmia

LVF

Pericardial effusion

Cardiomyopathy

Volume depletion

Dehydration

Haemorrhage

Burns

Gut losses (vomiting, fistula, diarrhoea)

Sepsis

Sequestration (pancreatitis, crush injury)

Renal losses (overdiuresis)

Hepatorenal syndrome (splanchnic vasodilatation)

Pre-renal causes exacerbation by ACE inhibitors and NSAIDS.

ACE inhibitors – impair AT2 production, leading to efferent arteriolar vasodilatation and reduced GFR

NSAIDS – impair cyclooxygenase inhibiting production of afferent vasodilatory eicosanoids

Renal (20-30%)

Acute tubular necrosis (see below)

Acute glomerulonephritis

Type 1 – anti-GBM antibodies (Goodpasture's disease)

Type 2 – Immune complex deposition (SLE etc)

Type 3 – ANCA positive (Wegeners' granulomatosis)

Acute interstitial nephritis

Drugs

NSAIDs

Antibiotics (penicillins, cephs, cipro, sulphonamides)

Infections

Streptococcus

Legionella

Viruses

Glomerulonephritis = proteinuria, haematuria and red cell casts

Rapidly progressive GN characterized by disease which produces extensive extracapillary proliferation (crescents) or necrosis.

AIN characteristically associated with sterile pyuria, white cell casts, eosinophiluria, and eosinophilia (up to 75%). Rash present in 25% Typically occurs 3-5 days after drug administration. Diagnosis = renal biopsy. Rx = drug cessation. Usually resolution in 3-7 days.

Post-renal (10%)

Obstructed anatomic or functioning solitary kidney

Stone

Tumour

Clot

Sloughed papilla

Stricture

Bilateral ureteric obstruction

RPF

Retroperitoneal tumour or lymphadenopathy

Cervical tumour

Bladder tumour

BPH with ureteric orifice distortion/obstruction

Chronic urinary retention

BPH

Bladder neck stenosis

Neuropathic bladder

Blocked catheter

Urinary fistula (urea and creatinine reabsorption)

Urinary findings in acute renal failure

Cause	Urinalysis	Urinary [Na]	Urine: plasma Cr	Fractional Na or RFI	Osmolality
Pre-renal	Hyaline casts or normal	<20	>30	<1	>500
RPGN	Red cell casts, RBCs, proteinuria	<20	>30	<1	>500
ATN	Granular casts, tubular cells	>40	<20	>1	<400
AIN	White cell casts, WBCs, eosinophils	>40	<20	>1	<400

NB. Urea:creatinine ratio high in pre-renal failure and low in intrinsic renal disease

$$\text{Fractional Excretion of Sodium (FE}_{\text{Na}}\text{)} = \frac{\frac{U_{\text{Na}} \times V}{U_{\text{creat}} \times V}}{P_{\text{creat}}} \times 100\%$$

$$\text{Renal Failure Index (RFI)} = \frac{U_{\text{Na}} \times P_{\text{creat}}}{U_{\text{creat}}}$$

Acute tubular necrosis

Commonest cause of renal failure in hospital setting

Renal hypoperfusion and ischaemia commonest cause of ATN; also due to endogenous/exogenous nephrotoxins

Endogenous nephrotoxins (Few)

Pigment nephropathy myoglobin (rhabdo in extended lithotomy)

haemoglobin

Crystal nephropathy uric acid, calcium oxalate

Tumour lysis syndrome

Exogenous nephrotoxins (Many – commonest below)

Contrast material

Antibiotics (aminoglycosides and amphotericin B)

Chemotherapeutic agents

NSAIDs

ACE inhibitors

Natural history Oliguric phase* <24 hours - 3 weeks
Typically 150-300 ml/day


Diuretic phase* SCr often continues to rise for 24-48 hours
Severe polyuria rare
25% of deaths seen in this phase

Recovery phase GFR resolution at 3 months

*Oliguria < 400ml/day

*Polyuria >3L day

Pathophysiology



Renal ischaemia = depletion of ATP = AMP accumulation = AMP metabolism to hypoxanthine, adenine and inositol (Hypoxanthine important substrate for oxygen free radical production during reperfusion). Loss of ATP results in myriad changes, the most important are seen above.

Clinical presentation and management of acute renal failure


Diagnosis

- History
- Clinical examination
 - Careful assessment of fluid status (JVP, failure, postural BP)
 - Abdominal examination (?bladder)
 - Rashes
- Chart review
 - Hypotensive episodes (ward chart or theatre record)
 - Drug frequency and dosage
- Urinalysis
 - See above
- Abdominal ultrasonography

Complications

- | | |
|------------------|---|
| Fluid overload | JVP, hypertension, pulmonary oedema |
| Electrolyte abn. | Low sodium and calcium |
| | High K, Mg, phosphate, acid (urate, H+) |
| Uraemia | a. Bleeding, anaemia |
| | b. Pleuritis, pulmonary oedema |
| | c. Pericarditis, cardiomyopathy |
| | d. Encephalopathy, confusion, fits, peripheral neuropathy |
| | g. N+V, diarrhea, GI bleed |
| | h. Impaired granulocyte + lymphocyte function |

Prognosis



Management

Three principles;

- Identify and remove any precipitant
- Provide supportive therapy
- Prevent complications

Conservative medical management

Fluid Balance

Carefully monitor intake/output and weights.

Restrict fluids.

Electrolytes and Acid-Base Balance

Prevent and treat hyperkalemia.

Avoid hyponatremia.

Keep serum bicarbonate > 15 mEq/L.

Minimize hyperphosphatemia.

Treat hypocalcemia only if symptomatic or if intravenous bicarbonate is required.

Uremia and Nutrition

Administer protein (1.0–1.8 g/kg/day) and maintain caloric intake; consider forms of nutritional support.

Keep carbohydrate intake at least 100 g/day to minimize ketosis and endogenous protein catabolism.

Drugs

Review all medications.

Stop magnesium-containing medications.

Adjust dosage for renal failure; readjust with improvement of glomerular filtration rate.

Treatment of hyperkalaemia

ECG monitoring > 6mmol/l

IV injection 10ml 10% calcium gluconate lasts 30-60 mins

Inhalation of 5mg salbutamol nebuliser lasts 30-60mins

10U insulin in 50ml 20% dextrose lasts ~6 hrs

Calcium resonium 15g tds lasts 6-8 hrs

Dialysis

Indications for dialysis*

Fluid overload unresponsive to diuretics

Severe hyperkalaemia (K > 6.5 mmol/l)

Severe metabolic acidosis (pH < 7.1)

Uraemic symptoms (>30 mmol/l)

Drug overdose with dialyzable toxin

* Vary from department to department. Values taken from Bellomo 1998 (ITU) dialysis-dependent renal injury reported due to hypotension and complement activation

CVVH associated with the least fluid shifts cf. HD or PD. – thus used in critical care setting

Conversion from oliguric to non-oliguric ARF

Controversial

Limited evidence that associated with better outcome, but 'creates space' allowing for easier administration of parenteral nutrition, drugs and fluids

Uncontrolled studies suggest that patients who respond to mannitol, frusemide or dopamine by producing a diuresis do better (Consentino 1995), but may simply reflect less severe disease from outset.

Loop diuretics

Flushes out obstructing casts and debris; reduces work of TALH

No evidence of benefit in terms of recovery, dialysis or death in placebo controlled RCTs (Shilliday 1997; Uchino 2004)

No evidence for increased mortality (BEST data; Uchino 2004)

Mannitol

Flushes tubules; reduces hypoxic cell swelling; free-radical scavenger

Limited evidence in animal studies; appears to reduce ischaemic insult if given immediately before clamping of renal artery at time of partial nephrectomy/renal transplant (animal studies only)

Dopamine

Renal dose 0.4 – 2.0 ug.kg/min

Selective renal vasodilation, natriuresis and increased RBF (dopamine 1 receptors)

One PC-RCT showed no evidence for benefit (Belloma 2000)

Also a/w dopamine 2 receptor (CNS), alpha adrenergic (vasoconstriction) and beta-adrenergic (increased cardiac contractility) side effects, leading in some cases to severe complications in critically ill

New selective DA-1 agonist (fenoldopam) shows promise in animal studies but has not been shown to be effective in preventing contrast induced nephropathy (Stone 2003)

ANP

Renal vasodilation, increased RBF

Experimental drug

One large PC-RCT showed no overall benefit but did improve outcome in a subset of patients with oliguric ATN (Rahman 1994)

Prevention of acute renal failure

Typically in contrast-induced nephrotoxicity

High risk patients

Elderly

Diabetes

Pre-existing renal failure

Evidence

Intravenous hydration better than none (Solomon 2004)

No evidence for additional benefit of diuretics

Non-ionic contrast better than ionic contrast media (Rudnick 1995)

? N-acetylcysteine

600mg bd for 48 hours pre-treatment

Conflicting evidence from metaanalyses (Alonso 2004;
Kshirsagar 2004)
However cheap, non-toxic and might work – often given
Sodium bicarbonate
Protective vs. N saline when given 1 hr pre-Ix (Merten 2004)

Chronic Renal Failure

<i>Cause and Frequency of End-stage Renal Disease</i>			
ADULT		PEDIATRIC	
Diabetes	34.2%	Glomerulonephritis	37.6%
Hypertension	29.4%	Congenital/other hereditary diseases	19.1%
Glomerulonephritis	14.2%	Collagen vascular diseases	9.9%
Cystic kidney diseases	3.4%	Obstructive nephropathy	6%
Interstitial nephritis	3.4%	Cystic kidney diseases	4.3%
Obstructive nephropathy	2.3%	Interstitial nephritis	4.2%
Collagen vascular diseases	2.2%	Hypertension	4.2%
Malignancies	1.3%	Diabetes	1.4%
		Malignancies	0.4%

Major impact on life expectancy: in dialysis patients;

22% die in first year

50% die within 3 yrs

67% die within 5 yrs

Primary cause of death due to cardiovascular disease; next infective complications

Complications of renal failure

Anaemia

low erythropoietin

Hypertension

sodium and water accumulation

Uraemia

peripheral neuropathy

Pleurisy and pericarditis

Cardiomyopathy

Renal osteodystrophy

reduced 1-alpha hydroxylation of vitamin D and reduced phosphate excretion = secondary hyperPTHism. Bone demineralization leads to lytic areas and #. Elevated calcium phosphate causes heterotopic calcification. Tertiary hyperPTHism may occur.

Proteinuria*

Hyperlipidaemia

Malnutrition

Impaired fertility

anovulation, ED, impaired spermatogenesis

Reduced libido

Pregnancy complication

increased preterm fetal loss (up to 16% in those with creat < 180 umol/l; more for higher values)
Increased likelihood of dialysis requirement

*Proteinuria

Degree of proteinuria predicts prognosis in patients with CKD

Some people report CKD levels with suffix 'p' if significant proteinuria

Protein/creatinine ration or albumin/creatinine ratio

Protein/creatinine ratio

100 = 1 g protein over 24 hours

300 = 3 g protein over 24 hours = nephrotic range

PCR not reliable if UTI, orthostatic, fever, exercise and menstruation

Classification

Stage 1	Renal damage with normal GFR	> 90 ml/min
Stage 2	Renal damage with mildly impaired GFR	< 90 ml/min
Stage 3	Renal damage with moderately impaired GFR	< 60 ml/min
Stage 4	Renal damage with severely impaired GFR	< 30ml/min
Stage 5	Established ESRF	< 15 ml/min

Management

Focus Area	Goal	Treatment
Blood pressure control	<130/80 if proteinuria < 1 g/day <125/75 if proteinuria > 1 g/day	Angiotensin-converting enzyme inhibitor
		Angiotensin receptor blocker
		Salt restriction
		Diuresis
Reduction in proteinuria	<0.5 g/day	Angiotensin-converting enzyme inhibitor
		Angiotensin receptor blocker
		? Aldosterone blockade
Glycemic control	HbA _{1c} < 7%	Oral hypoglycemic agents
		Diet
		Insulin
Dietary protein restriction	0.6 to 0.8 g/kg/d _{1.73}	Dietary consult
Lipid lowering	Low-density lipoprotein level ≥ 70 mg/dL _{1.73}	Statin ^[†] [4]
		Triglyceride-lowering agent
Anemia management	Hemoglobin > 12 g/dL	Erythropoietin
		Iron
Lifestyle modifications	Ideal body weight _{1.73}	Weight loss program (dietary counseling, st
	Smoking cessation	Antidepressants
	Exercise three times per week	
	Depression modification	
Calcium × phosphorus product	<4.5 mmol/L	Vitamin D supplementation
	<55 mg/dL	Use of dietary phosphorus restriction
	Phosphorus < 5.5 mg/dL (1.78 mmol)	Phosphate binders
	Intact parathyroid hormone level of 70 to 110 pg/mL (CKD stage 4)	
	30–70 pg/mL (CKD stage 3)	
	25(OH)vitamin D > 30 ng/mL	

NB. EPO ineffective in patients with inadequate iron stores. Oral supplementation generally does raise iron levels enough ? low transferring. Therefore IV iron supplementation often required

Chronic renal replacement therapy

Typically indicated by creatinine clearance 10ml/min

HD, CAPD, renal transplantation

USA 60% HD; 30% functioning renal transplant; 10% CAPD

Complications

HD	thrombosis, vascular access problems
CAPD	catheter problems, peritonitis, constipation, poor compliance
Transplant	see chapter on renal transplantation




Figure 10-5 Haemodialysis

Filtration AND diffusion across a semi-permeable membrane. Usually over 4 hours. Associated with relatively high fluid shifts. Cardiac function must be reasonable to accommodate these. Typically 4-5 hours.




Figure 10-7b VenoVenous Haemofiltration

Filtration only. Largely historical. Superseded by haemodiafiltration




Figure 10-8 Haemodiafiltration

Typically filtration AND fluid replacement. Runs continuously. Takes much longer than HD, but better tolerated cardiovascularly. Therefore useful in ITU and in CVS patients. Also has larger pore size – therefore may be suitable for patients with amyloidosis.

- CAPD Continuous ambulatory dialysis
 Usually 2L bags of Dextrose into abdomen
 Osmotic gradient across peritoneum
 Need to get waste products out of peritoneum before dextrose absorbed and osmotic gradient reverses – different concentrations of dextrose and dwell times
- | | |
|---------------------|-----------------------------|
| Weak (yellow) | 1.36% glucose |
| Medium (green) | 2.27% glucose |
| Strong (orange) | 3.86% glucose |
| Amino-acids (blue) | Glucose-sparing (diabetics) |
| Icodextrin (purple) | Long-acting HMW molecule |
| | Overnight bag |
- Common prescription = 3 yellow and overnight icodextrin
- Complications
- Peritonitis
 - Constipation
 - Hernias
 - Catheter complications
 - Poor compliance

Haemodialysis access

Permanent

Fistulae

- Radiocephalic
- Brachiocephalic
- Brachio basilic

Grafts

Tunnelled lines

- Subclavian (Hickmann line)

Temporary lines

- Femoral
- Jugular

Complications of fistulae

- Failure
- Infection
- Thrombosis
- Steal syndrome

1.

Chronic kidney disease (CKD)

CKD 1: GFR >90 ml/min/1.73m²

CKD 2: GFR 60–90 ml/min/1.73m²

CKD 3: GFR 30–60 ml/min/1.73m²

CKD 4: GFR 15–30 ml/min/1.73m²

CKD 5: GFR <15 ml/min/1.73m² and/or peritoneal or haemodialysis

Recent modification - 3 subdivided into 3a and 3b

1	>90	ml/min/1.73
2	60-90	ml/min/1.73
3a	45-59	ml/min/1.73
3b	30-44	ml/min/1.73
4	15-29	ml/min/1.73
5	<15	ml/min/1.73